Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline Journal Article


Authors: Konstantinopoulos, P. A.; Norquist, B.; Lacchetti, C.; Armstrong, D.; Grisham, R. N.; Goodfellow, P. J.; Kohn, E. C.; Levine, D. A.; Liu, J. F.; Lu, K. H.; Sparacio, D.; Annunziata, C. M.
Article Title: Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline
Abstract: PURPOSETo provide recommendations on genetic and tumor testing for women diagnosed with epithelial ovarian cancer based on available evidence and expert consensus.METHODSA literature search and prospectively defined study selection criteria sought systematic reviews, meta-analyses, randomized controlled trials (RCTs), and comparative observational studies published from 2007 through 2019. Guideline recommendations were based on the review of the evidence.RESULTSThe systematic review identified 19 eligible studies. The evidence consisted of systematic reviews of observational data, consensus guidelines, and RCTs.RECOMMENDATIONSAll women diagnosed with epithelial ovarian cancer should have germline genetic testing for BRCA1/2 and other ovarian cancer susceptibility genes. In women who do not carry a germline pathogenic or likely pathogenic BRCA1/2 variant, somatic tumor testing for BRCA1/2 pathogenic or likely pathogenic variants should be performed. Women with identified germline or somatic pathogenic or likely pathogenic variants in BRCA1/2 genes should be offered treatments that are US Food and Drug Administration (FDA) approved in the upfront and the recurrent setting. Women diagnosed with clear cell, endometrioid, or mucinous ovarian cancer should be offered somatic tumor testing for mismatch repair deficiency (dMMR). Women with identified dMMR should be offered FDA-approved treatment based on these results. Genetic evaluations should be conducted in conjunction with health care providers familiar with the diagnosis and management of hereditary cancer. First- or second-degree blood relatives of a patient with ovarian cancer with a known germline pathogenic cancer susceptibility gene variant should be offered individualized genetic risk evaluation, counseling, and genetic testing. Clinical decision making should not be made based on a variant of uncertain significance. Women with epithelial ovarian cancer should have testing at the time of diagnosis. (c) 2020 by American Society of Clinical Oncology
Keywords: double-blind; shared decision-making; brca mutation; fallopian-tube; mismatch repair deficiency; american society; parp; microsatellite instability detection; olaparib maintenance therapy; homologous recombination genes; inhibitor rucaparib
Journal Title: Journal of Clinical Oncology
Volume: 38
Issue: 11
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2020-04-10
Start Page: 1222
End Page: 1245
Language: English
ACCESSION: WOS:000526811600012
DOI: 10.1200/jco.19.02960
PROVIDER: wos
PUBMED: 31986064
Notes: Article -- Source: Wos
Altmetric
Citation Impact
MSK Authors
  1. Rachel Nicole Grisham
    53 Grisham